Competitive Information. Each of the parties acknowledges and understands that the other party may now market or have under development products or services which are competitive with products or services now offered or which may be offered by the other party, and, except as expressly set forth in this Agreement, the parties’ communications hereunder will not serve to impair the right of either party to develop, make, use, procure or market products or services now or in the future which may be competitive with those offered by the other party, nor require either party to disclose any planning or other information to the other party.
Competitive Information. A. Potential competitors
Competitive Information. Commercially Sensitive Terms.
Competitive Information. Financial Provisions. 16 Competitive Information – Financial Provisions and Commercially Sensitive Terms. 17 Competitive Information – Commercially Sensitive Terms.
Competitive Information. You should never attempt to obtain a competitor’s confidential information by improper means, and you should especially never contact a competitor regarding their confidential information. While the Company may, and does, employ former employees of competitors, we recognize and respect the obligations of those employees not to use or disclose the confidential information of their former employers.
Competitive Information. GBT has not requested and does not want any confidential information belonging to a prior employer. Employee must not use such information (except such information previously belonging to Westbound Bank which was merged with and into GBT) in the performance of his or her duties for GBT nor should Employee share any such information with any other employees of GBT.
Competitive Information. The Sellers represent and warrant that save and except for the Not Yet Delivered Competitive Information (within the meaning of Section 5.6), the Sellers have made available all documents which the Sellers view as containing Competitive Information to Xxxxx and Xxxxx & Xxxxx LLP ("E&Y"). The Purchaser acknowledges that Xxxxx and E&Y have
Competitive Information. The Parties shall consult with outside antitrust counsel before any competitively sensitive information (including price information, strategic and marketing plans and customer-specific information) is provided to the Parent Group pursuant to Section 10.1.
Competitive Information. Discovery Information. 12 Competitive Information – Discovery Information. 13 Competitive Information – Discovery Information. 14 Competitive Information – Discovery Information. 15 Competitive Information – Discovery Information. 16 Competitive Information – Discovery Information. 17 Competitive Information – Discovery Information. 18 Competitive Information – Discovery Information. 19 Competitive Information – Discovery Information and Other Commercially Sensitive Terms. 20 Competitive Information – Discovery Information and Other Commercially Sensitive Terms. 21 Competitive Information – Discovery Information and Other Commercially Sensitive Terms. 22 Competitive Information – Discovery Information and Other Commercially Sensitive Terms. 23 Competitive Information – Discovery Information and Other Commercially Sensitive Terms. 24 Competitive Information – Discovery Information. 25 Competitive Information – Discovery Information. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZYMEWORKS INC. IF PUBLICLY DISCLOSED. INFORMATION THAT HAS BEEN OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE XXXX “[…***…]”.
Competitive Information. A. Potential competitors: gemcitabine, TarcevaÒ and nab-paclitaxel (likely) GemzarÒ injection (Gemcitabine hydrochloride) Current treatment options for patients with cancer of the pancreas are limited, and little clinically significant progress has been made since US FDA approval of gemcitabine in 1996. GemzarÒ, a cytidine analog, was approved for the treatment of locally advanced or metastatic pancreatic cancer. The Phase 3 study of gemcitabine involved 126 pancreatic cancer subjects - 63 of these received gemcitabine therapy and the other 63 subjects received treatment with 5-FU1. Of these subjects, more than 70% entered the study with metastatic disease, the most advanced stage of pancreatic cancer. Gemcitabine demonstrated a statistically significant advantage in survival over 5-FU. Gemcitabine subjects had a 5.7 month median survival compared with 4.2 months for 5-FU subjects, a six-week advantage in median survival. Based on this trial, the six-month probability estimate for survival of subjects treated with gemcitabine was 46% (30 patients), compared with 29% (19 subjects) for 5-FU subjects. After one year, the survival probability estimate was 18% (9 subjects) for gemcitabine, compared with 2% (two subjects) for 5-FU. The most frequent reason for reducing or limiting the dose of gemcitabine was neutropenia, which was observed in 63% of subjects, (with NCI Common Toxicity Criteria Severity Grade III/IV in 25% of subjects). Other common adverse effects in gemcitabine clinical trials included nausea and vomiting (69%), fever (41%), edema or fluid retention (up to 34%), rash (30%), and flu-like symptoms (19%). Reversible alopecia was reported in 15% of subjects. About 10% of all subjects participating in gemcitabine clinical trials discontinued therapy due to side effects2. TarcevaÒ tablets (erlotinib hydrochloride) In November 2005 the FDA approved erlotinib hydrochloride, a kinase inhibitor (TarcevaÒ tablets, made by OSI Pharmaceuticals Inc.) in combination with gemcitabine for the treatment of patients with locally advanced, unresectable or metastatic pancreatic carcinoma. This combination therapy approval was based upon a single Phase 3 randomized trial of 569 patients in which the median overall survival of the erlotinib/gemcitabine group vs. the gemcitabine alone group was 6.24 months vs. 5.91 months. The 10-day improvement was a statistically, although not a particularly clinically, significant difference. The overall response rate (XXX, defined...
